Skip to main content

Table 1 Baseline patient characteristics according to invasive ductal and invasive lobular histological subtype

From: A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population

 

IDC group (n = 14,547)

ILC group (n = 528)

P-value

Age

   

Mean ± SD

48.5 ± 10.3

48.9 ± 9.3

0.297

Median (range)

47.0 (19.0 to 93.0)

47.0 (24.0 to 82.0)

0.321

<50

8736 (60.1)

323 (61.2)

0.109

50≤

5811 (39.9)

205 (38.8)

 

Tumor size

   

Mean ± SD

2.3 ± 1.4

2.9 ± 1.9

<0.001

Median (range)

2.0 (0.1 to 16.0)

2.5 (0.3 to 14.0)

<0.001

T ≤ 2 cm

7,556 (51.9)

218 (41.3)

<0.001

2 cm < T ≤ 5 cm

6,341 (43.6)

251 (47.5)

 

5 cm < T

650 (5.2)

59 (11.2)

 

Nodal status

   

0

8238 (56.6)

289 (54.7)

0.248

1 to 3

4067 (28.0)

141 (26.7)

 

4 to 9

1481 (10.2)

67 (12.7)

 

10≤

761 (5.2)

31 (5.9)

 

TNMstage

   

stage I

5323 (36.6)

166 (31.4)

0.001

stage II

6819 (46.9)

244 (46.2)

 

stage III

2405 (16.5)

118 (22.4)

 

Lymphatic invasion

   

no

9,337 (64.2)

343 (65.0)

0.714

yes

5,210 (35.8)

185 (35.0)

 

Vascular invasion

   

no

11,794 (81.1)

387 (73.3)

<0.001

yes

2,753 (18.9)

141 (26.7)

 

Estrogen receptor status

   

negative

5,698 (39.2)

103 (19.5)

<0.001

positive

8,849 (60.8)

425 (80.5)

 

Progesterone receptor status

   

negative

6,370 (43.8)

134 (25.4)

<0.001

positive

8,177 (56.2)

394 (74.6)

 

HER2

   

negative

11,381 (78.2)

496 (93.9)

<0.001

positive

3,166 (21.8)

32 (6.1)

 

Radiation therapy

   

no

6,570 (45.2)

265 (50.2)

0.023

yes

7,977 (54.8)

263 (49.8)

 

Chemotherapy

   

no

2,499 (17.2)

96 (18.2)

0.549

yes

12,048 (82.8)

432 (81.8)

 

Hormonal therapy

   

no

4,549 (31.3)

81 (15.3)

<0.001

yes

9,998 (68.7)

447 (84.7)

 

Surgery

   

mastectomy

8,112 (55.8)

354 (67.1)

<0.001

breast conserving surgery

6,435 (44.2)

174 (32.9)

 

Molecular subtype

   

luminal A

8,196 (56.3)

439 (83.2)

<0.001

luminal B

1,638 (11.3)

25 (4.7)

 

HER2-overexpression

1,528 (10.5)

7 (1.3)

 

Triple negative

3,185 (21.9)

57 (10.8)

 
  1. Data are express as the n (%), means ± SD and median (range).
  2. HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.